Trial Profile

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danburstotug (Primary)
Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms NeoChance

Most Recent Events

10 Apr 2025 Status changed from recruiting to active, no longer recruiting.
19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
27 Apr 2021 According to a Sorrento Therapeutics media release, this study is nearing completion.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com